Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop ...

DelveInsight's "Systemic Lupus Erythematosus Pipeline Insight, 2025" report delivers comprehensive insights about 120+ companies and 140+ pipeline drugs currently in the various s ...

AstraZeneca Plc said a handful of patients with lupus went into remission after getting an experimental treatment, as the UK ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in systemic lupus erythematosus, according to data presented at the EULAR 2025 ...

GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support ...

Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company redefining the treatment of autoimmune and ...

Flare and persistently active disease are prevalent in a multinational cohort study of patients with systemic lupus erythematosus, with some having persistently active disease without flare.

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...

On May 7, 2025, the American College of Rheumatology (ACR) released the full guideline for diagnosing, monitoring, and treating lupus nephritis (LN), which appeared in Arthritis & Rheumatology.

The Member of Parliament (MP) for Korle Klottey in Accra, Dr Zanetor Agyeman-Rawlings, has called for the inclusion of lupus ...

The Johns Hopkins Department of Dermatology is seeking volunteers with cutaneous lupus to participate in a research study ...